Document is current

Article History

Accepted: 18 February 2022

First Online: 3 March 2022

Declarations

:

: L.D.M. has received fees to give lectures from Gilead, MSD, ViiV, AbbVie, and Janssen-Cilag. M.L. received fees to give lectures from Gilead, MSD, ViiV, AbbVie, and Janssen-Cilag. A.U. has received fees to give lectures from Gilead, ViiV, and Janssen-Cilag. L.L. and B.T. have received fees to give lectures from Gilead, MSD, ViiV, AbbVie, and Janssen-Cilag. A.G.C. has received fees to give lectures and advisory board from Gilead, MSD, ViiV, AbbVie, and Janssen-Cilag. A.I. has received educational grants from MSD and Gilead. JA has participated in advisory boards and received consulting honoraria, research grants, or both, from Gilead Sciences, Janssen Pharmaceuticals, and ViiV Healthcare, all outside of this work. E.M. has received honoraria for lectures or advisory boards from Gilead and Janssen and his institution has received research grants from MSD and ViiV. J.L.B. has received honoraria for lectures or advisory boards from Gilead, Janssen, MSD. L.M. has received honoraria for lectures from Lundbeck, Gilead, and Neuraxpharm. J.B. has received honoraria for lectures or advisory boards from Ferrer Internacional, Gilead, Janssen, MSD, and ViiV. DS is an employee of ViiV Healthcare and shareholder of GlaxoSmithKline. J.M. has received honoraria, speakers’ fees, consultant fees, or funds for research from MSD, Roche, Boehringer-Ingelheim, ViiV, Gilead, Janssen, BMS, AbbVie. M.M.R. has received fees to give lectures from Gilead, MSD, ViiV, AbbVie, and Janssen-Cilag. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. E.D.L. Z.E., A. R, and J. Bosch have nothing to disclose.